Literature DB >> 25347007

Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time.

R Parody1, R Martino2, R de la Cámara3, A García-Noblejas3, A Esquirol2, I Garcia-Cadenas2, T Villaescusa4, D Caballero4, M Rovira5, F Fernandez-Avilés5, F J Marquez-Malaver1, I Espigado1, C Castilla-Llorente6, I Heras6, M A Cabero7, J R Cabrera7, P Barba8, D Valcarcel8, I Sánchez-Ortega9, R F Duarte9, D Serrano10, F Carretero10, L Vazquez4.   

Abstract

Umbilical cord blood (CB) is increasingly used as an alternative source of stem cells in adult unrelated transplantation. Although registry studies report similar overall outcomes in comparison with BM/PB, comparative studies focusing on severe infections and infection-RM (IRM) with a long follow-up are scarce. A total of 434 consecutive unrelated transplants (1997-2009) were retrospectively analyzed to compare overall outcomes, incidence and risk factors of severe viral and invasive fungal infections in CB (n=65) vs BM/PB recipients (n=369). The 5-year OS was 38 vs 43%, respectively (P=0.2). CB transplantation (CBT) was associated with a higher risk of invasive aspergillosis (100-days-cumulative incidence 16 vs 6%, P=0.04) and CMV infection without differences in RM. No statistically significant differences were found regarding NRM (NRM of 38% in CB vs 37% in BM/PB at 1 year) nor IRM (30% in CB vs 27% in BM/PB at 1 year). In the overall population, NRM and IRM improved in more recent years. In adults who receive a single CBT, the risk of severe infections is increased when compared with unrelated BM/PB recipients, but mortality from infections is similar, leading to similar NRM and survival.

Entities:  

Mesh:

Year:  2014        PMID: 25347007     DOI: 10.1038/bmt.2014.229

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  42 in total

Review 1.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation.

Authors:  K M Sullivan; E Agura; C Anasetti; F Appelbaum; C Badger; S Bearman; K Erickson; M Flowers; J Hansen; T Loughran
Journal:  Semin Hematol       Date:  1991-07       Impact factor: 3.851

Review 2.  Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation.

Authors:  Simona Iacobelli
Journal:  Bone Marrow Transplant       Date:  2013-03       Impact factor: 5.483

3.  Early infections in adult patients undergoing unrelated donor cord blood transplantation.

Authors:  S Saavedra; G F Sanz; I Jarque; F Moscardó; C Jiménez; I Lorenzo; G Martín; J Martínez; J De La Rubia; R Andreu; S Mollá; I Llopis; M J Fernández; M Salavert; B Acosta; M Gobernado; M A Sanz
Journal:  Bone Marrow Transplant       Date:  2002-12       Impact factor: 5.483

Review 4.  Definitions of cytomegalovirus infection and disease in transplant recipients.

Authors:  Per Ljungman; Paul Griffiths; Carlos Paya
Journal:  Clin Infect Dis       Date:  2002-03-11       Impact factor: 9.079

5.  CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus.

Authors:  Małgorzata Mikulska; Anna Maria Raiola; Paolo Bruzzi; Riccardo Varaldo; Silvana Annunziata; Teresa Lamparelli; Francesco Frassoni; Elisabetta Tedone; Barbara Galano; Andrea Bacigalupo; Claudio Viscoli
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-27       Impact factor: 5.742

6.  Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.

Authors:  Vanderson Rocha; Myriam Labopin; Guillermo Sanz; William Arcese; Rainer Schwerdtfeger; Alberto Bosi; Niels Jacobsen; Tapani Ruutu; Marcos de Lima; Jürgen Finke; Francesco Frassoni; Eliane Gluckman
Journal:  N Engl J Med       Date:  2004-11-25       Impact factor: 91.245

7.  Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis.

Authors:  J N Barker; S M Davies; T DeFor; N K Ramsay; D J Weisdorf; J E Wagner
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

8.  Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.

Authors:  J Sanz; J C H Boluda; C Martín; M González; C Ferrá; D Serrano; C D de Heredia; C Barrenetxea; A M Martinez; C Solano; M A Sanz; G F Sanz
Journal:  Bone Marrow Transplant       Date:  2012-02-13       Impact factor: 5.483

9.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

10.  Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes.

Authors:  S McCann; J L Byrne; M Rovira; P Shaw; P Ribaud; S Sica; L Volin; E Olavarria; S Mackinnon; P Trabasso; M T VanLint; P Ljungman; K Ward; P Browne; A Gratwohl; A F Widmer; C Cordonnier
Journal:  Bone Marrow Transplant       Date:  2004-03       Impact factor: 5.483

View more
  2 in total

1.  Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization.

Authors:  Sarah Anand; Samantha Thomas; Terry Hyslop; Janet Adcock; Kelly Corbet; Cristina Gasparetto; Richard Lopez; Gwynn D Long; Ashley K Morris; David A Rizzieri; Keith M Sullivan; Anthony D Sung; Stefanie Sarantopoulos; Nelson J Chao; Mitchell E Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2017-04-06       Impact factor: 5.742

2.  Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation.

Authors:  Karen Ballen; Kwang Woo Ahn; Min Chen; Hisham Abdel-Azim; Ibrahim Ahmed; Mahmoud Aljurf; Joseph Antin; Ami S Bhatt; Michael Boeckh; George Chen; Christopher Dandoy; Biju George; Mary J Laughlin; Hillard M Lazarus; Margaret L MacMillan; David A Margolis; David I Marks; Maxim Norkin; Joseph Rosenthal; Ayman Saad; Bipin Savani; Harry C Schouten; Jan Storek; Paul Szabolcs; Celalettin Ustun; Michael R Verneris; Edmund K Waller; Daniel J Weisdorf; Kirsten M Williams; John R Wingard; Baldeep Wirk; Tom Wolfs; Jo-Anne H Young; Jeffrey Auletta; Krishna V Komanduri; Caroline Lindemans; Marcie L Riches
Journal:  Biol Blood Marrow Transplant       Date:  2016-06-22       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.